March 1, 2023
Chugai Pharmaceutical said on February 28 that it has submitted an application seeking a label expansion for its anti-human IL-6 receptor monoclonal antibody Actemra (tocilizumab) for an additional indication of cytokine release syndrome (CRS) induced by cancer treatment. In Japan,...read more